

**NOTICE OF NEW HAMPSHIRE MEDICAID FEE FOR SERVICE
DRUG UTILIZATION REVIEW BOARD
PUBLIC HEARING
June 8, 2021**

The New Hampshire Drug Utilization Review (DUR) Board invites you to attend a public hearing at 2:00 p.m., on June 8, 2021 via Zoom Conference. The DUR meeting will immediately follow this public hearing. The Zoom Conference information will be available 1 week prior to the DUR meeting at

<https://www.dhhs.nh.gov/ombp/pharmacy/notices.htm>

and

<https://newhampshire.magellanmedicaid.com/portal/spring/public/nhportalpublic?execution=e1s1>.

The purpose of the public hearing is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid Fee for Service pharmacy prior authorization criteria and preferred drug list (PDL) class additions.

The public hearing will begin at 2:00 p.m. and end no later than 3:00 p.m. The DUR meeting will begin at or before 3:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the proposed prior authorization criteria and PDL additions. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the prior authorization criteria and PDL class additions.

Written material may also be submitted by the public for DUR Board consideration, if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

If accommodations are needed for communication access such as interpreters, CART (captioning), assistive listening devices, or other auxiliary aids and/or services, please contact Nancy Plourde at (603) 271-9422 by May 25, 2021. At least 5 business days advance notice is requested in order to assure availability; requests made fewer than 5 days prior to the event will attempt to be accommodated but cannot be guaranteed.

**DRUG UTILIZATION REVIEW BOARD MEETING
June 8, 2021
Meeting Agenda**

- I. Introductions and Welcome to Board Members
- II. Old Business
 - A. Minutes – 12/15/2020 review
- III. New Business
 - A. DUR Business Operations
 - 1. Overview of Drug Utilization Patterns for the New Hampshire Medicaid Fee-for Service Program
 - a. Prospective DUR Reports
 - b. Utilization Reports

c. Retrospective DUR Reports

B. COVID-19 Status Update

C. Review of Current Clinical Prior Authorization Criteria with Proposed Changes

1. Allergen Extracts
2. Asthma/Allergy Immunomodulators
3. Drugs for Bowel Disorders/GI Motility, Chronic
4. Calcitonin Gene-Related Peptide (CGRP) Inhibitor
5. Direct Renin Inhibitor and Combination
6. Duchenne Muscular Dystrophy Agents
7. Hematopoietic Agents
8. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
9. Short-Acting Fentanyl Analgesic
10. Systemic Immunomodulators

D. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes

1. Benign Prostatic Hyperplasia

E. Proposal of New Clinical Prior Authorization Criteria

1. Evyrsdi™
2. Spravato®

F. Proposal of Criteria to Retire

1. Syndros™ (dronabinol)

G. Proposal of New Preferred Drug List (PDL) Category

1. Calcitonin Gene-Related Peptide (CGRP) Inhibitors – Migraine Treatment
2. Idiopathic Pulmonary Fibrosis
3. Ophthalmics – Anti-inflammatory/Immunomodulator
4. Opiate Dependence Treatment – Buprenorphine-Containing - Injectable
5. Pituitary Suppressive Agents, LHRH

IV. Adjourn

Further information regarding the agenda items may be obtained after May 25, 2021. Notice of intent to testify at the public hearing, and/or submittal of written comments, should be directed to Nancy Plourde, NH Department of Health and Human Services, 129 Pleasant Street, Concord, NH, 03301, (603) 271-9422, or e-mail at: Nancy.T.Plourde@dhhs.nh.gov.